New hope for kids battling tough leukemia
NCT ID NCT06191978
Summary
This study aims to find a safe and effective dose of a two-drug combination (venetoclax and ASTX727) for children and teenagers whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It will enroll up to 40 participants aged 2 to 18 years old. The main goals are to determine the best dose, check for side effects, and see if the treatment helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.